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Abstract
Background: Hypoxia seems to be an influencing factor for oral squamous cell carcinomas (SCC), and several
immunohistochemical markers have been discussed in this regard. The aim of the present study was to evaluate
preoperative hemoglobin levels as a prognostic factor for oral SCC.
Materials and methods: The files of 287 patients who had been treated for oral SCC between 1999 and 2008
were studied retrospectively. Hemoglobin levels between 1 and 5 days prior to surgical treatment were compared
to Tumor (T)- and Nodal (N)- status, local recurrence, and lymph node metastases rate. The minimum follow-up
period was 12 months.
Results: From a total of 287 patients with oral SCC, 205 (71.4%) were in the normal hemoglobin (Hb) group
(female Hb≥12.0 g/dl; male Hb≥13.0 g/dl), 53 (18.5%) in the mild anemia (female Hb = 11.0-11.9 g/dl; male Hb =
11.0-12.9 g/dl), and 29 (10.1%) in the severe anemia group (female & male Hb<11.0 g/dl). Anemia was significant
for the development of lymph node metastasis (p = 0.005) as well as for local recurrence (p = 0.001). No significant
correlation was found to the initial T status (p = 0.183).
Conclusion: Our data suggests that an Hb of below 11 g/dl contributes to and is an indicator for a poor
prognosis. Consequently, pre-treatment Hb corrections may significantly improve outcome, but further
investigations, including blood transfusion/application of erythropoietin due to tumor anemia, independent of
intraoperative blood-loss are necessary to ascertain their role in an improved survival.
Background
The estimated number of newly diagnosed cancers of
the oral cavity and pharynx is 97,800 per year in Europe;
the estimated number of deaths due to these carcinomas
is 40,100 per year [1]. Despite improved diagnostic tools,
chemotherapy, radiotherapy, and improved surgical
techniques, the 5-year survival rate for head and neck
cancer seems to be unchanged over the last two
decades.
Clinical features and progression can differ greatly:
some tumors develop no metastases, while others infil-
trate at a very early stage and develop lymphangiomato-
sis or perineural invasion; such complications are not
limited to well known risk factors such as smoking,
alcohol consumption, poor mouth hygiene, or human
papilloma virus (HPV). But the reason why the out-
comes of some tumors are so much worse than those of
others has still not been discovered. One of the most
important prognostic factors for lymph node metastasis
in head and neck cancer is tumor infiltration depth[2],
but the reason for different histological growth patterns
and lymphogenic metastases is still unknown.
Hypoxia seems to be an influencing factor for oral
squamous cell carcinomas (SCC), and it is well known
that the radiation doses needed to kill hypoxic cells are
approximately 2-3 times higher than those needed to
destroy well-oxygenated cells[3,4]. Most studies for head
and neck SCC, however, deal with the effect of anemia
as it relates to the outcome of radiotherapy[5,6]. There-
fore, the question arises whether anemia also influences
the outcome of surgical treatment. We have come
across no studies which have dealt with this subject.
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Materials and methods
A total of 287 patients who were treated for oral SCC over
a 10-year period between 1999 and 2008 at a single center
(Clinic for Craniomaxillofacial and Oral Surgery, Univer-
sity Hospital Zurich) were evaluated retrospectively. All
hemoglobin levels between 1 and 5 days prior to surgical
treatment, Tumor (T)- and Nodal (N)-statuses, local
recurrence rates, and lymph node metastases were taken
into consideration. The minimum follow-up time was 12
months. Due to inadequate information and/or a follow-
up time of less than 12 months, 82 patients were excluded.
Using the normal hemoglobin (Hb) values defined by
the World Health Organization (WHO), the patients
were divided into a three groups: normal (female
Hb≥12.0 g/dl; male Hb≥13.0 g/dl), mild anemia (female
Hb = 11.0-11.9 g/dl; male Hb = 11.0-12.9 g/dl), and
severe anemia (female & male Hb<11.0 g/dl), according
to Becker et al. [5]
All data were primarily obtained for medical purpose
under informed consent of the patients. The study
design fulfills the criteria of paragraphs 4a and b accord-
ing to the guidelines (version 21.5.2010.2010) of the can-
tonal ethics committee of Zurich and therefore is
exempted from institutional review board approval. The
study design thereby fulfills the guidelines of the
Declaration of Helsinki about Ethical Principles for
Medical Research Involving Human Subjects.
For statistical analysis, SPPS 18 for Mac was used. P
value < 0.05 was considered to be statistically significant.
Kaplan-Meier analysis with log-rank testing was used for
analysis.
Results
Out of 287 patients with oral SCC, 205 (71.4%) were in
the normal group, 53 (18.5%) in the mildly anemic, and
29 (10.1%) in the severely anemic group. The female-
male ratio was 121:166, and the median age 62.53 years.
In the log rank test, anemia was significant for the
development of lymph node metastasis (p = 0.005) as
well as for the development of local recurrence (p =
0.001) (Figure 1 and 2).
No association between T status and the development
of local recurrence was found (p = 0.183) (Figure 3).
In the severe anemia group, 17 out of 29 patients
(58.6%) had T4 status; in the normal group, 58 out of
205 patients (28.3%) had T4 status. There was a low
number of patients with T3 status (Figure 4).
Lymph node metastases were observed in 45 out of
205 (28.1%) patients in the normal group and, in the
severe anemia group, 19 out of 29 (65.5%) patients had
positive lymph nodes (Figure 5).
Discussion
It is widely accepted that anemia causes radiation resis-
tance because the Hb level presumably mediates tumor
response to radiation through the delivery of oxygen to
the tumor[5]. There is increasing evidence that low Hb
levels are indeed associated with poor tumor oxygena-
tion, and increasing Hb concentrations are correlated
with higher pO2 levels and lower hypoxic tissue frac-
tions[7]. Therefore, several authors advocate blood
transfusions before radiotherapy for anemic patients
[8-10].
Figure 1 Kaplan-Meier curves of lymph node metastasis -free survival for patients without anemia, mild anemia, or severe anemia.
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In the current study, low Hb levels were found to be
associated with the development of lymph node
metastasis (p = 0.005). Concerning the development of
local recurrence, anemia is also a prognostic factor (p
= 0.001), but, surprisingly, not the initial T status (p =
0.183). These data suggest that a low Hb concentra-
tion contributes to poor prognosis; these findings
were supported by the results of several previous stu-
dies[11,12].
One reason could be that hypoxia is induced via
Hypoxia-inducible Factor-1a (HIF-1a) and Vascular
endothelial growth factor (VEGF), leading to a loss of
p53[13].
If a low Hb concentration is a predictor of decreased
local control, consequently, Hb corrections may signifi-
cantly improve tumor oxygenation.
On the other hand, out of 29 patients in the severe
anemia group, 17 had T4 tumors; therefore, large/
Figure 2 Kaplan-Meier curves of local recurrence-free survival for patients without anemia, mild anemia, or severe anemia.
Figure 3 Kaplan-Meier curves of local recurrence-free survival for patients with T1-, T2-, T3-, and T4-status.
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infiltrative tumors might have led to anemia. However
our data did not reveal T-status influence on local
recurrence or lymph node metastases. Another reason
could be the advanced stage of the disease. In the pre-
sent study, 65.5% of patients with severe anemia had
lymph node metastases, but, in the normal group, only
28.1% had positive lymph nodes.
However, if a lower Hb is associated with a worse out-
come, one could conclude that blood transfusion could
improve prognosis. To our knowledge, no study has
dealt with this question. However, several studies have
dealt with the need for intraoperative blood transfusion.
(Table 1) This topic is not identical but somehow simi-
lar since low preoperative Hb-levels might - assumed
surgical procedures are identical - lead to an intraopera-
tive need for transfusion. However, evidence of a signifi-
cant association between transfusion and prognosis in
patients who undergo resection of oral SCC is conflict-
ing: some authors have reported an influence [14,15],
while others did not confirm blood transfusion as a
prognostic factor[16,17]. After all, one must also differ-
entiate between blood transfusions for preoperative ane-
mia and those for surgical procedure/bleeding, as
mentioned above.
Figure 4 Distribution of T status and grade of anemia.
Figure 5 Distribution of N status and grade of anemia.
Table 1 Studies regarding blood transfusion in head and neck cancer patients
Author Patients (n) Location Outcome Results
Böck[24] 174
(141 with transfusion)
Larynx/hypopharynx Recurrence, survival, infection No influence
Jones[25] 90
(46 with transfusion)
Head and neck Recurrence No influence
Ell[26] 240
(113 with transfusion)
Larynx Survival No influence
Woolley[27] 143
(99 with tranfusion)
Head and neck Recurrence P < 0.009
Von Doersten[28] 104
(51 with transfusion)
Head and neck Recurrence, infection No influence
Schuller[17] 217
(132 with transfusion)
Head and neck Survival No influence
Barra[29] 207
(152 with transfusion)
Head and neck Survival P < 0.05
Alun-Jones[30] 69
(38 with transfusion)
Larynx Survival P < 0.05
Sturgis[14] 61
(25 with transfusion)
Head and neck Recurrence Influence
(48% with transfusion; 24% without transfusion)
Leon[31] 269
(86 with transfusion)
Larynx Recurrence No influence
Moir[32] 165 (60 with transfusion) Head and neck Recurrence P < 0.04
Taniguchi[15] 105
(64 with transfusion)
Oral cavity Survival P < 0.01
Szakmany[33] 559
(437 with transfusion)
Oral cavity/
Oropharyngeal
Recurrence,
survival
≥3 units influence
Fenner[16] 223 Oral cavity Survival No influence
Studies involving the effects of blood transfusion in head and neck cancer show inconsistent results
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For patients with colorectal, lung, or breast carcinoma,
an immunosuppressive effect of blood transfusions lead-
ing to increased local recurrence has been discussed,
but is doubted by some authors[18,19], and it has not
been proven so far for head and neck cancer. There is
also some laboratory evidence for an association
between blood transfusion and tumor growth[20].
One hypothesized mechanism for a worsened prog-
nosis in tumor patients undergoing blood transfusion is
the presence of biologically active growth factors in
stored blood products. These factors seem to leach from
red blood cells [21-23]
The strength of this study lays in the high number of
patients with a minimum follow-up time (12 months)
compared to smaller numbers of patients with head and
neck cancer written about in the literature.
The limitation of the study is its retrospective nature.
Conversely, the analysis was restricted to those variables
that could be retrieved reliably for every patient from
our database. Therefore, the number of blood transfu-
sions and the amount of intraoperative blood-loss were
excluded. In addition, other risk factors such as smok-
ing, alcohol use, and poor mouth hygiene were not
included because that information was not known. The
number of patients with T3 status in this study is low
and not consistent with T-status distribution of SCC
found in many other studies and is not the distribution
one would expect. However, this fact should not influ-
ence the results.
The idea of advocating preoperative transfusion or
erythropoietin administration prior to surgery has very
important economic as well as physiologic consequences
and, given the grade of evidence, we consider this idea
only with caution. Further investigations are needed,
including examination of blood transfusion/application
of erythropoietin due to tumor anemia in a prospective
setting with multivariate analysis to rule out dependency
with other more important factors. The influence of all
negative side effects possibly coming with the transfu-
sion of blood products also needs to be addressed[21].
Also there are several reasons why patients with head
and neck tumors may have low preoperative hemoglo-
bin, such as nutritional deficiency, difficulties involving
oral intake, and/or social deprivation. Anemia could also
be a marker for other risk factors, such as p53 mutation,
loss of heterozygosity (LOH), HPV, etc. These factors
should also be considered in future prospective studies.
In sum, the results of this study were not expected
and no satisfying explanation is obvious. However, if it
is found that Hb is not independent, it might still be an
important and easily obtained marker for underlying
conditions the cause for poor prognosis.
Conclusion
Our data suggest that a low Hb level contributes to poor
prognosis in oral SCC patients. Consequently, Hb cor-
rections may significantly improve outcomes, but further
investigations are necessary to clear the role of Hb in
outcome prediction for oral SCC.
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